---
title: "Xinbang Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 152 million yuan, a year-on-year decrease of 13.74%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263069703.md"
description: "According to the Zhitong Finance APP, Xinbang Pharmaceutical released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 4.266 billion yuan, a year-on-year decrease of 6.55%. The net profit attributable to shareholders of the listed company was 152 million yuan, a year-on-year decrease of 13.74%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 157 million yuan, a year-on-year decrease of 10.50%"
datetime: "2025-10-28T11:24:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263069703.md)
  - [en](https://longbridge.com/en/news/263069703.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263069703.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/263069703.md) | [繁體中文](https://longbridge.com/zh-HK/news/263069703.md)


# Xinbang Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 152 million yuan, a year-on-year decrease of 13.74%

According to the Zhitong Finance APP, Xinbang Pharmaceutical (002390.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 4.266 billion yuan, a year-on-year decrease of 6.55%. The net profit attributable to shareholders of the listed company was 152 million yuan, a year-on-year decrease of 13.74%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 157 million yuan, a year-on-year decrease of 10.50%

### Related Stocks

- [xinbang phar. (002390.CN)](https://longbridge.com/en/quote/002390.CN.md)